ESMO 2016 | The significance of fulvestrant for hormone receptor-positive advanced breast cancer
Matthew Ellis, MB, BChir, PhD, FRCP of Baylor College of Medicine, Houston, TX discusses the significance of fulvestrant for hormone receptor-positive advanced breast cancer. Metastatic breast cancer and in particular hormone receptor-positive advanced breast cancer, is not an immediate death sentence as Prof. Ellis explains. Many patients do well with different endocrine manipulations and with fulvestrant, we have a potential drug to extend the durability of these initial endocrine responses; this is a key result of the FALCON trial (NCT01602380). He explains that the patients responding to fulvestrant had better quality responses, which means that they are not in need of more complicated therapies or chemotherapy.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up